W1454: Colon Polyp Miss Rate on Colonoscopy - On Patients Diagnosed As Early Colon Cancer After Polypectomy

2010 ◽  
Vol 71 (5) ◽  
pp. AB332
Author(s):  
Hyun Gun Kim ◽  
Jin-Oh Kim ◽  
Tae Hee Lee ◽  
Won Young Cho ◽  
Seong Ran Jeon ◽  
...  
2009 ◽  
Vol 49 (1) ◽  
pp. 63-69 ◽  
Author(s):  
Irina Corin ◽  
Lisa Larsson ◽  
Jörgen Bergström ◽  
Bengt Gustavsson ◽  
Kristoffer Derwinger

2015 ◽  
Vol 3 (2) ◽  
pp. 52-55
Author(s):  
Umid Kumar Shrestha

Background: Lower gastrointestinal bleeding (LGIB) is a common clinical condition associated with significant morbidity and mortality. The aims of our study were to determine the etiological profile, gender difference and age group patterns of LGIB in Nepal.Methods: A total of 415 consecutive patients presenting with LGIB from April 2011 to September 2014 underwent colonoscopy and the etiology of LGIB was determined. Each diagnosis was compared with respect to the gender and age group.Results: Among 415 LGIB patients (males 62.2%, females 37.8%), the different etiologies of LGIB were as following: hemorrhoid 35.2%, non-specific colitis 24.8%, colon polyp 18.3%, inflammatory bowel disease (IBD) 10.4%, colon cancer 6.5%, diverticulosis 1.7%, unknown 1.4%, upper gastrointestinal bleeding 1.2% and radiation colitis 0.5%. The overall LGIB was more common in male; however, colon polyps were diagnosed more commonly in female (p<0.001). Among LGIB patients, the hemorrhoid was more common in the age group of 30-49 years, colon polyp in 50-69 years, colon cancer in 70-84 years, and non-specific colitis and IBD in 16-29 years (p<0.001).Conclusion: Hemorrhoid and non-specific colitis were the common causes of LGIB in Nepal; colon polyp, IBD and colon cancer were the next common causes. More males presented with LGIB than females; however, colon polyp was diagnosed more in females, which needs to be explored further. When LGIB was presented after 50 years of age, the most likely causes were colon polyp and colon cancer; hence colonoscopy is recommended in all LGIB patients after 50 years.Journal of Advances in Internal Medicine 2014;3(2):52-55


In Vivo ◽  
2020 ◽  
Vol 34 (5) ◽  
pp. 2277-2280
Author(s):  
YOSHIHIKO TASHIRO ◽  
HANNAH M. HOLLANDSWORTH ◽  
HIROTO NISHINO ◽  
JUN YAMAMOTO ◽  
SIAMAK AMIRFAKHRI ◽  
...  

2018 ◽  
Vol 21 (4) ◽  
pp. E8
Author(s):  
Ernestine Clements ◽  
Lena Gamble ◽  
Nathan Way ◽  
Lacy Smith ◽  
John B. Waits

2019 ◽  
Vol 18 ◽  
pp. 117693511882280 ◽  
Author(s):  
Chase Cockrell ◽  
David E Axelrod

Cancer chemotherapy dose schedules are conventionally applied intermittently, with dose duration of the order of hours, intervals between doses of days or weeks, and cycles repeated for weeks. The large number of possible combinations of values of duration, interval, and lethality has been an impediment to empirically determine the optimal set of treatment conditions. The purpose of this project was to determine the set of parameters for duration, interval, and lethality that would be most effective for treating early colon cancer. An agent-based computer model that simulated cell proliferation kinetics in normal human colon crypts was calibrated with measurements of human biopsy specimens. Mutant cells were simulated as proliferating and forming an adenoma, or dying if treated with cytotoxic chemotherapy. Using a high-performance computer, a total of 28 800 different parameter sets of duration, interval, and lethality were simulated. The effect of each parameter set on the stability of colon crypts, the time to cure a crypt of mutant cells, and the accumulated dose was determined. Of the 28 800 parameter sets, 434 parameter sets were effective in curing the crypts of mutant cells before they could form an adenoma and allowed the crypt normal cell dynamics to recover to pretreatment levels. A group of 14 similar parameter sets produced a minimal time to cure mutant cells. A different group of nine similar parameter sets produced the least accumulated dose. These parameter sets may be considered as candidate dose schedules to guide clinical trials for early colon cancer.


BMC Cancer ◽  
2019 ◽  
Vol 19 (1) ◽  
Author(s):  
Xin Xie ◽  
Jianhao Yin ◽  
Zhangjian Zhou ◽  
Chengxue Dang ◽  
Hao Zhang ◽  
...  

2020 ◽  
Vol 35 (8) ◽  
pp. 1607-1613
Author(s):  
You Jin Lee ◽  
Jung Wook Huh ◽  
Jung Kyong Shin ◽  
Yoon Ah Park ◽  
Yong Beom Cho ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document